Glaucoma MIGS and Meds: Keeping an Eye on New Advances is organized by Healio.
Release Date: October 30, 2023
Expiration Date: October 31, 2024
Activity Description:
The burden of irreversible vision loss from glaucoma continues to rise. Early intervention is key, but despite the effectiveness of available anti-glaucoma therapies, compliance continues to be problematic. Many of the topical glaucoma therapies, particularly those that include preservatives, can cause damage to the ocular surface, resulting in a lack of tolerability that may limit adherence. While they can be an effective initial therapy in many patients, studies have shown that it is often necessary to use multiple topical medications to achieve a target intraocular pressure (IOP). Improved drug-delivery systems may be one solution to this problem, and several sustained-release delivery systems are under investigation to mitigate the burden of daily medication.
Regarding surgical approaches for glaucoma, treatment modalities such as minimally invasive glaucoma surgery (MIGS) offer rapid and effective reduction of IOP, maintain a good safety profile, and use ab interno procedures with minimal tissue trauma and faster recovery. The vast number of recently developed MIGS techniques not only provided clinicians with a wide range of therapeutic options but also they have enabled physicians to refine their therapies, contributing to a more patient-centered decision-making process.
This educational activity will explore the sustained-release medications that can improve overall outcomes and compliance with therapy as well as the available MIGS procedures for patients with glaucoma. Expert faculty will review the supporting clinical data for each therapeutic approach and provide practical tips when employing these therapies, including individualizing therapy for specific patients.
Learning Objectives:
Upon successful completion of this activity, participants should be better able to:
• Describe novel, minimally invasive glaucoma surgical procedures that can improve overall outcomes in patients.
• Recognize how the use of sustained-release glaucoma medications can improve adherence and compliance with therapy.